Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Tóm tắt
Từ khóa
Tài liệu tham khảo
DeFronzo, 1988, Lilly Lecture 1987. The triumvirate: cell, muscle, liver. A collusion responsible for NIDDM, Diabetes, 37, 667, 10.2337/diab.37.6.667
DeFronzo, 1997, Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes, Diabetes Rev, 3, 177
Kelley, 1995, Effects of weight loss on glucose homeostasis in NIDDM, Diabetes Rev, 3, 366
Schneider, 1995, Effects of fitness and physical training on carbohydrate metabolism and associated cardiovascular risk factors in patients with diabetes, Diabetes Rev, 3, 378
DeFronzo, 1985, Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulindependent (type II) diabetes mellitus, J Clin Invest, 76, 149, 10.1172/JCI111938
Groop, 1989, Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance, J Clin Invest, 84, 205, 10.1172/JCI114142
Shulman, 1990, Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by 13C nuclear magnetic resonance spectroscopy, N Engl J Med, 322, 223, 10.1056/NEJM199001253220403
DeFronzo, 1989, Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake, Metabolism, 38, 387, 10.1016/0026-0495(89)90129-7
Gulli, 1992, The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents, Diabetes, 41, 1575, 10.2337/diab.41.12.1575
Tripathy, 2000, Insulin secretion and insulin sensitivity in relation to glucose tolerance. Lessons from the Botnia Study, Diabetes, 49, 975, 10.2337/diabetes.49.6.975
Pratipanawatr, 2001, Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation, Diabetes, 50, 2572, 10.2337/diabetes.50.11.2572
Jackson, 2000, Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant nondiabetic relatives of type 2 diabetic families, Diabetes, 49, 1169, 10.2337/diabetes.49.7.1169
Yalow, 1960, Immunoassay of endogenous plasma insulin in man, J Clin Invest, 39, 1157, 10.1172/JCI104130
Diamond, 1993, Glucose metabolism during the menstrual cycle: assessment by the euglycemic, hyperinsulinemic clamp technique, J Reprod Med, 38, 417
Reaven, 1989, Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance, Diabetologia, 32, 52, 10.1007/BF00265404
Vauhkonen, 1997, Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. Metabolic studies on offspring of diabetic probands, J Clin Invest, 100, 86
Weyer, 1999, Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance, Diabetes, 48, 2197, 10.2337/diabetes.48.11.2197
Mitrakou, 1992, Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance, N Engl J Med, 326, 22, 10.1056/NEJM199201023260104
Polonsky, 1996, Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the cell to compensate for insulin resistance, N Engl J Med, 334, 777, 10.1056/NEJM199603213341207
Kahn, 2001, The importance of cell failure in the development and progression of type 2 diabetes, J Clin Endocrinol Metab, 86, 4047
Jensen, 2002, Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S, Diabetes, 51, 2170, 10.2337/diabetes.51.7.2170
Bogardus, 1984, Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects, J Clin Invest, 74, 1238, 10.1172/JCI111533
Saad, 1989, Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes, Lancet, 1, 1356, 10.1016/S0140-6736(89)92804-3
Ferrannini, 1988, The disposal of an oral glucose load in patients with non-insulin dependent diabetes, Metabolism, 37, 79, 10.1016/0026-0495(88)90033-9
Harris, 1998, Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U. S. adults. The Third National Health and Nutrition Examination Survey 1988-94, Diabetes Care, 21, 518, 10.2337/diacare.21.4.518
Pi-Sunyer, 1996, Weight and non-insulin-dependent diabetes mellitus, Am J Clin Nutr, 63, 426S, 10.1093/ajcn/63.3.426
Knowler, 1981, Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes, Am J Epidemiol, 113, 144, 10.1093/oxfordjournals.aje.a113079
Carey, 1997, Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study, Am J Epidemiol, 45, 614, 10.1093/oxfordjournals.aje.a009158
Mokdad, 2000, Diabetes trends in the United States 1990-98, Diabetes Care, 23, 1278, 10.2337/diacare.23.9.1278
Perry, 1999, Serum true insulin concentration and the risk of clinical non-insulin dependent diabetes during long-term follow-up, Int J Epidemiol, 28, 735, 10.1093/ije/28.4.735
Burke, 2001, Elevated incidence of type 2 diabetes in San Antonio, Texas, compared with that of Mexico City, Mexico, Diabetes Care, 24, 1573, 10.2337/diacare.24.9.1573
DeFronzo, 1978, Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding, J Clin Invest, 62, 204, 10.1172/JCI109108
Kolterman, 1980, Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects, J Clin Invest, 65, 1272, 10.1172/JCI109790
Ferrannini, 1997, Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR), J Clin Invest, 100, 1166, 10.1172/JCI119628
Bjorntorp, 1991, Metabolic implications of body fat distribution, Diabetes Care, 14, 1132, 10.2337/diacare.14.12.1132
Chan, 1994, Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men, Diabetes Care, 17, 961, 10.2337/diacare.17.9.961
Clausen, 1996, Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors, J Clin Invest, 98, 1195, 10.1172/JCI118903
Kissebah, 1989, Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus, Diabetes Metab Rev, 5, 83, 10.1002/dmr.5610050202
Despres, 1995, The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications, Int J Obes Related Metab Disord, 19, S76
Banerji, 1995, Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive?, Diabetes, 44, 141, 10.2337/diab.44.2.141
Bonora, 1992, Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women, Diabetes, 41, 1151, 10.2337/diab.41.9.1151
Albu, 2000, Fat distribution and health in obesity, Ann N Y Acad Sci, 904, 491, 10.1111/j.1749-6632.2000.tb06505.x
Zierath, 1998, Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signaling through the insulin receptor substrate-1-pathway, Diabetologia, 41, 1343, 10.1007/s001250051075
Reaven, 1988, Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM, Diabetes, 37, 1020, 10.2337/diab.37.8.1020
Boden, 2002, Free fatty acids in obesity and type 2 diabetes. defining their role in the development of insulin resistance and cell dysfunction, Eur J Clin Invest, 32, 14, 10.1046/j.1365-2362.32.s3.3.x
Reaven, 1995, The fourth musketeer-from Alexandre Dumas to Claude Bernard, Diabetologia, 38, 3, 10.1007/BF02369347
Golay, 1988, Metabolic basis of obesity and noninsulin-dependent diabetes mellitus, Diabetes Metab Rev, 4, 727, 10.1002/dmr.5610040803
Boden, 1997, Role of fatty acids in the pathogenesis of insulin resistance and NIDDM, Diabetes, 46, 3, 10.2337/diab.46.1.3
McGarry, 2002, Banting Lecture 2001. dysregulation of fatty acid metabolism in the etiology of type 2 diabetes, Diabetes, 51, 7, 10.2337/diabetes.51.1.7
Kashyap, 2002, Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of T2DM, Diabetes, 51, A12
Goodpaster, 2000, Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus, Am J Clin Nutr, 71, 885, 10.1093/ajcn/71.4.885
Greco, 2002, Insulin resistance in morbid obesity. Reversal with intramyocellular fat depletion, Diabetes, 51, 144, 10.2337/diabetes.51.1.144
Seppala-Lindroos, 2002, Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men, J Clin Endocrinol Metab, 87, 3023, 10.1210/jcem.87.7.8638
Miyazaki, 2002, Effect of pioglitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in patients with type 2 diabetes mellitus, Diabetes, 51, A69
Prentki, 1996, Are the B-cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM?, Diabetes, 45, 273, 10.2337/diab.45.3.273
Unger, 1996, Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. genetic and clinical implications, Diabetes, 45, 273
Shimabukuro, 1998, Fatty acid induced cell apoptosis, Proc Natl Acad Sci USA, 95, 2498, 10.1073/pnas.95.5.2498
Randle, 1963, The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, 1, 785, 10.1016/S0140-6736(63)91500-9
Felber, 1981, Glucose storage and oxidation in different degrees of human obesity measured by continuous indirect calorimetry, Diabetologia, 20, 39, 10.1007/BF00253814
Golay, 1984, Study on lipid metabolism in obesity diabetes, Metabolism, 33, 111, 10.1016/0026-0495(84)90121-5
Thiebaud, 1982, Effect of long chain triglyceride infusion on glucose metabolism in man, Metabolism, 21, 1128, 10.1016/0026-0495(82)90163-9
Roden, 1999, Rapid impairment of skeletal muscle glucose transport / phosphorylation by free fatty acids in humans, Diabetes, 48, 358, 10.2337/diabetes.48.2.358
Kelley, 2000, Fuel selection in human skeletal muscle in insulin resistance, Diabetes, 49, 677, 10.2337/diabetes.49.5.677
De Fea, 1997, Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612, Biochemistry, 36, 12939, 10.1021/bi971157f
Ravichandran, 2001, PKC-phosphorylates IRS-1 and impairs its ability to activate P-3-kinase in response to insulin, J Biol Chem, 276, 3543, 10.1074/jbc.M007231200
Faergeman, 1997, Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signaling, Biochem J, 323, 1, 10.1042/bj3230001
Kruszynska, 2002, Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation, J Clin Endocrinol Metab, 87, 226, 10.1210/jcem.87.1.8187
Dresner, 1999, Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity, J Clin Invest, 103, 253, 10.1172/JCI5001
Kashyap, 2002, A chronic physiologic increase in FFA in healthy subjects causes insulin signaling defects similar to those of insulin-resistant nondiabetic subjects with a strong family history of T2DM, Diabetes, 51, A24
Thompson, 2000, Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance, Diabetes, 49, 1761, 10.2337/diabetes.49.11.1761
Tippett, 1982, Anallosteric model for the inhibition of glucokinase by long chain acyl coenzyme A, J Biol Chem, 257, 14846
Wititsuwannakul, 1977, Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase, J Biol Chem, 252, 7812, 10.1016/S0021-9258(17)41039-8
Schmitz-Peiffer, 1999, Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate, J Biol Chem, 274, 24202, 10.1074/jbc.274.34.24202
Chavez, 2003, A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids, J Biol Chem, 278, 10297, 10.1074/jbc.M212307200
DeFronzo, 1978, Influence of hyperinsulinemia, hyperglycemia, and the route of glucose administration on splanchnic glucose exchange, Proc Natl Acad Sci USA, 75, 5173, 10.1073/pnas.75.10.5173
DeFronzo, 1983, Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia, Diabetes, 32, 35, 10.2337/diab.32.1.35
Cherrington, 1999, Banting Lecture. Control of glucose uptake and release by the liver in vivo, Diabetes, 48, 1198, 10.2337/diabetes.48.5.1198
Mittelman, 2000, Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin, Am J Physiol, 279, E630
Bevilacqua, 1987, Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects, Metabolism, 36, 502, 10.1016/0026-0495(87)90051-5
Golay, 1987, Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals, Metabolism, 36, 692, 10.1016/0026-0495(87)90156-9
Exton, 1969, Control of gluconeogenesis in liver. IV. Differential effects of fatty acids and glucagon on ketogenesis and gluconeogenesis in the perfused rat liver, J Biol Chem, 244, 4095, 10.1016/S0021-9258(17)36389-5
Bahl, 1997, In vitro and in vivo suppression of gluconeogenesis by inhibition of pyruvate carboxylase, Biochem Pharmacol, 53, 67, 10.1016/S0006-2952(96)00660-0
Williamson, 1966, Mechanisms for the stimulation of gluconeogenesis by fatty acids in perfused rat liver, Proc Natl Acad Sci USA, 56, 247, 10.1073/pnas.56.1.247
Massillon, 1997, Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion, Diabetes, 46, 153, 10.2337/diab.46.1.153
Lam, 2003, Mechanisms of the free fatty acid-induced increase in hepatic glucose production, Am J Physiol, 284, E863
Kim, 2001, Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance, Proc Natl Acad Sci USA, 98, 7522, 10.1073/pnas.121164498
Baron, 1987, Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics, Diabetes, 36, 274, 10.2337/diab.36.3.274
Matsuda, 2002, Dose-response curve relating plasma glucagon to hepatic glucose production and glucose disposal in type 2 diabetes mellitus, Metabolism, 51, 1111, 10.1053/meta.2002.34700
Waldhausl, 1982, Insulin production rate, hepatic insulin retention, and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinemic type II (non-insulin dependent) diabetes mellitus, Diabetologia, 23, 6, 10.1007/BF00257722
McGarry, 1999, Fatty acids, lipotoxicity and insulin secretion, Diabetologia, 42, 128, 10.1007/s001250051130
Warnotte, 1994, Mechanisms of the stimulation of insulin release by saturated fatty acids: a study of palmitate effects of mouse B-cells, Diabetes, 43, 703, 10.2337/diab.43.5.703
Stein, 1996, Essentially of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat, J Clin Invest, 97, 2728, 10.1172/JCI118727
Matschinsky, 1996, Banting Lecture 1995: a lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm, Diabetes, 45, 223, 10.2337/diab.45.2.223
Newgard, 1995, Metabolic coupling factors in pancreatic cell signal transduction, Annu Rev Biochem, 64, 689, 10.1146/annurev.bi.64.070195.003353
Zhou, 1994, Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle, J Clin Invest, 93, 870, 10.1172/JCI117042
Sako, 1990, A 48-h lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and cell oxidation through a process likely coupled to fatty acid oxidation, Endocrinology, 127, 1580, 10.1210/endo-127-4-1580
Mason, 1999, Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats, Diabetes, 48, 524, 10.2337/diabetes.48.3.524
Zhou, 1995, Long term exposure to fatty acids and ketones inhibits b-cell function in human pancreatic islets of Langerhans, J Clin Endocrinol Metab, 80, 1584
Unger, 1997, How obesity causes diabetes in Zucker diabetic fatty rats, Trends Endocrinol Metab, 7, 276, 10.1016/S1043-2760(97)00094-5
Lupi, 2002, Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets. Evidence that cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated, Diabetes, 51, 1437, 10.2337/diabetes.51.5.1437
Carpentier, 1999, Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation, Am J Physiol, 276, E1055
Paolisso, 1995, Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects, Diabetologia, 38, 1295, 10.1007/BF00401761
Carpentier, 2000, Prolonged elevation of plasma free fatty acids impair pancreatic B-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes, Diabetes, 49, 399, 10.2337/diabetes.49.3.399
Stefan, 2001, Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferators- activated receptor-2 gene, Diabetes, 50, 1143, 10.2337/diabetes.50.5.1143
Szczepaniak, 1999, GaMeasurement of intracellular triglyceride stores by H spectroscopy: validation in vivo, Am J Physiol, 276, E977
Perseghin, 1999, Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents, Diabetes, 48, 1600, 10.2337/diabetes.48.8.1600
Krssak, 1999, Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study, Diabetologia, 42, 113, 10.1007/s001250051123
Stein, 1999, Increasing intramyocellular triglyceride stores are associated with impaired glucose tolerance and NIDDM, Diabetes, 48, A287
Pan, 1997, Skeletal muscle triglyceride levels are inversely related to insulin action, Diabetes, 46, 983, 10.2337/diab.46.6.983
Sewter, 2002, Regional differences in the response of human pre-adipocytes to PPARγ and RXRα agonists, Diabetes, 51, 718, 10.2337/diabetes.51.3.718
Goodpaster, 1999, Effects of weight loss on regional fat distribution and insulin sensitivity in obesity, Diabetes, 48, 839, 10.2337/diabetes.48.4.839
Kelley, 1999, Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss, Am J Physiol, 277, E1130
Greco, 2002, Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion, Diabetes, 51, 144, 10.2337/diabetes.51.1.144
Bajaj, 2003, Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes mellitus, Diabetes, 52, 1364, 10.2337/diabetes.52.6.1364
Bajaj, 2004, Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients, J Clin Endocrinol Metab, 89, 200, 10.1210/jc.2003-031315
Ryysy, 2000, Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients, Diabetes, 49, 749, 10.2337/diabetes.49.5.749
Pickup, 1998, Is type II diabetes mellitus a disease of the innate immune system?, Diabetologia, 41, 1241, 10.1007/s001250051058
Festa, 2000, Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS), Circulation, 102, 42, 10.1161/01.CIR.102.1.42
Fruhbeck, 2001, The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation, Am J Physiol, 280, E827
Bjorntorp, 1990, ‘Portal’ adipose tissue as a generator of risk factors for cardiovascular disease and diabetes, Arteriosclerosis, 10, 493, 10.1161/01.ATV.10.4.493
Arner, 2001, Regional differences in protein production by human adipose tissue, Biochem Soc Trans, 29, 72, 10.1042/bst0290072
Motoshima, 2002, Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes. effects of insulin and rosiglitazone, J Clin Endocrinol Metab, 87, 5662, 10.1210/jc.2002-020635
Berg, 2001, The adipocytesecreted protein Acrp30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992
Combs, 2001, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, J Clin Invest, 108, 1875, 10.1172/JCI14120
Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 7, 941, 10.1038/90984
Weyer, 2001, Hypoadiponectinemia in obesity and type 2 diabetes. close association with insulin resistance and hyperinsulinemia, J Clin Endocrinol Metab, 86, 1930, 10.1210/jcem.86.5.7463
Hotta, 2001, Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys, Diabetes, 50, 1126, 10.2337/diabetes.50.5.1126
Arita, 1999, Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun, 257, 79, 10.1006/bbrc.1999.0255
Hotta, 2000, Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients, Arterioscler Thromb Vasc Biol, 20, 1595, 10.1161/01.ATV.20.6.1595
Lazar, 2002, Resistin and obesity-associated insulin resistance, Trends Endocrinol Metab, 13, 18, 10.1016/S1043-2760(01)00522-7
Savage, 2001, Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans, Diabetes, 50, 2199, 10.2337/diabetes.50.10.2199
Wang, 2002, Human resistin gene. molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians, J Clin Endocrinol Metab, 87, 2520, 10.1210/jcem.87.6.8528
Krakoff, 2003, Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian, Diabetes Care, 26, 1745, 10.2337/diacare.26.6.1745
Yang, 2002, Synthetic peroxisome proliferator activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients, Diabetes Care, 25, 376, 10.2337/diacare.25.2.376
Scherer, 1995, A novel serum protein similar to C1q, produced exclusively in adipocytes, J Biol Chem, 270, 26746, 10.1074/jbc.270.45.26746
Hunter, 1998, Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system, Am J Med, 105, 331, 10.1016/S0002-9343(98)00300-3
Rajala, 2003, Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production, J Clin Invest, 111, 225, 10.1172/JCI16521
McTernan, 2002, Increased resistin gene and protein expression in human abdominal adipose tissue, J Clin Endocrinol Metab, 87, 2407, 10.1210/jcem.87.5.8627
Vidal-Puig, 2001, Resistin: a new link between obesity and insulin resistance?, Clin Endocrinol (Oxf ), 55, 437, 10.1046/j.1365-2265.2001.01377.x
McTernan, 2002, Resistin, central obesity, and type 2 diabetes, Lancet, 359, 46, 10.1016/S0140-6736(02)07281-1
McTernan, 2002, Depot-specific expression of resistin in human adipose tissue and regulation of resistin secretion by insulin and rosiglitazone in human subcutaneous adipocytes in vitro, Diabetologia, 45, A66
Bajaj, 2004, Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type 2 diabetic patients, Internat J Obesity, 28, 783, 10.1038/sj.ijo.0802625
Haugen, 2001, Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes, FEBS Lett, 507, 105, 10.1016/S0014-5793(01)02968-4
Hartman, 2002, Mechanisms regulating adipocyte expression of resistin, J Biol Chem, 277, 19754, 10.1074/jbc.M201451200
Shojima, 2002, Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells, Diabetes, 51, 1737, 10.2337/diabetes.51.6.1737
Saye, 1989, Angiotensinogen gene expression in 3T3-L1 cells, Am J Physiol, 256, C448, 10.1152/ajpcell.1989.256.2.C448
Karlsson, 1998, Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II, J Clin Endocrinol Metab, 83, 3925
Hainault, 2002, Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa /fa) Zucker rat, Am J Physiol, 282, E59
Hsueh, 1999, Insulin signaling in the arterial wall, Am J Cardiol, 84, 21J, 10.1016/S0002-9149(99)00353-7
Goetze, 1999, Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells, FEBS Lett, 452, 277, 10.1016/S0014-5793(99)00624-9
Yudkin, 1999, Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?, Diabetes Care, 22, C25
Juhan-Vague, 1997, PAI-I, obesity, insulin resistance and risk of cardiovascular events, Thromb Haemost, 78, 656, 10.1055/s-0038-1657607
Alessi, 1997, Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease, Diabetes, 46, 860, 10.2337/diab.46.5.860
Alessi, 2000, Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity, Diabetes, 49, 1374, 10.2337/diabetes.49.8.1374
Birgel, 2000, Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes, Arterioscler Thromb Vasc Biol, 20, 1682, 10.1161/01.ATV.20.6.1682
Ryden, 2002, Mapping of early signaling events in tumor necrosis factor-α-mediated lipolysis in human fat cells, J Biol Chem, 277, 1085, 10.1074/jbc.M109498200
Hotamisligil, 1993, Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance, Science, 259, 87, 10.1126/science.7678183
Feinstein, 1993, Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates, J Biol Chem, 268, 26055, 10.1016/S0021-9258(19)74276-8
Hotamisligil, 1996, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance, Science, 271, 665, 10.1126/science.271.5249.665
Hotamisligil, 1995, Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance, J Clin Invest, 95, 2409, 10.1172/JCI117936
Miyazaki, 2003, Tumor necrosis factor α and insulin resistance in obese type 2 diabetic patients, Int J Obesity, 27, 88, 10.1038/sj.ijo.0802187
Nilsson, 1998, Relation between plasma tumor necrosis factor-_and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus, Arterioscler Thromb Vasc Biol, 18, 1199, 10.1161/01.ATV.18.8.1199
Zinman, 1999, Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus, J Clin Endocrinol Metab, 84, 272
Spiegelman, 1998, PPAR-gamma: adipogenic regulator and thiazolidinedione receptor, Diabetes, 47, 507, 10.2337/diabetes.47.4.507
Mohamed-Ali, 1997, Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo, J Clin Endocrinol Metab, 82, 4196
Van Snick, 1990, Interleukin 6: an over-view, Annu Rev Immunol, 8, 253, 10.1146/annurev.iy.08.040190.001345
Sandler, 1990, Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro, Endocrinology, 126, 1288, 10.1210/endo-126-2-1288
Pradhan, 2001, C-Reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus, JAMA, 286, 327, 10.1001/jama.286.3.327
Pickup, 2000, Plasma interleukin-6, tumour necrosis factor and blood cytokine production in type 2 diabetes, Life Sci, 67, 291, 10.1016/S0024-3205(00)00622-6
Zhang, 1994, Positional cloning of the mouse obese gene and its human homologue, Nature, 372, 425, 10.1038/372425a0
Halaas, 1995, Weight-reducing effects of the plasma protein encoded by the obese gene, Science, 269, 543, 10.1126/science.7624777
Montague, 1998, Depot-related gene expression in human subcutaneous and omental adipocytes, Diabetes, 47, 1384, 10.2337/diabetes.47.9.1384
Ceddia, 1999, Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation, Int J Obesity Related Metab Disord, 23, 75, 10.1038/sj.ijo.0800762
Kamohara, 1997, Acute stimulation of glucose metabolism in mice by leptin treatment, Nature, 389, 374, 10.1038/38717
Muoio, 2002, Peripheral metabolic actions of leptin, Best Prac Res Clin Endocrinol Metab, 16, 653, 10.1053/beem.2002.0223
Ranganathan, 1998, Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells, Endocrinology, 139, 2509, 10.1210/endo.139.5.5980
Mantzoros, 2000, Editorial: leptin as a therapeutic agent-trials and tribulations, J Clin Endocrinol Metab, 85, 4000
Clement, 1998, A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction, Nature, 392, 398, 10.1038/32911
Farooqi, 1999, Effects of recombinant leptin therapy in a child with congenital leptin deficiency, N Engl J Med, 341, 879, 10.1056/NEJM199909163411204
Gainsford, 1996, Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells, Proc Natl Acad Sci USA, 93, 14564, 10.1073/pnas.93.25.14564
Fernandes, 1978, Immune response in the mutant diabetic C57BL/Ks-dt+ mouse. Discrepancies between in vitro and in vivo immunological assays, J Clin Invest, 61, 243, 10.1172/JCI108933
Chandra, 1980, Cell-mediated immunity in genetically obese C57BL/6J ob/ob mice, Am J Clin Nutr, 33, 13, 10.1093/ajcn/33.1.13
Choy, 1992, Adipsin and an endogenous pathway of complement from adipose cells, J Biol Chem, 267, 12736, 10.1016/S0021-9258(18)42338-1
Cianflone, 1999, Acylation stimulating protein (ASP), an adipocyte autocrine: new directions, Semin Cell Dev Biol, 10, 31, 10.1006/scdb.1998.0272
Maslowska, 1999, Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations, Eur J Clin Invest, 29, 679, 10.1046/j.1365-2362.1999.00514.x
Mudaliar, 2001, New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers, Annu Rev Med, 52, 239, 10.1146/annurev.med.52.1.239
Fonseca, 1998, Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group, J Clin Endocrinol Metab, 83, 3169
Saltiel, 1996, Thiazolidinediiones in the treatment of insulin resistance in type 2 diabetes, Diabetes, 45, 1661, 10.2337/diab.45.12.1661
Aronoff, 1996, Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group, Diabetes Care, 23, 1605, 10.2337/diacare.23.11.1605
Miyazaki, 2001, Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone, Diabetes Care, 24, 710, 10.2337/diacare.24.4.710
Miyazaki, 2002, Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients, J Clin Endocrinol Metab, 87, 2784, 10.1210/jcem.87.6.8567
Miyazaki, 2001, Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients, Diabetologia, 44, 2210, 10.1007/s001250100031
Inzucchi, 1998, Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus, N Engl J Med, 338, 867, 10.1056/NEJM199803263381303
Maggs, 1998, Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 128, 176, 10.7326/0003-4819-128-3-199802010-00002
Olfesky, 2000, Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists, J Clin Invest, 106, 467, 10.1172/JCI10843
Kim, 2002, Troglitazone but not metformin restores insulinstimulated phosphoinositide 3-kinase activity and increases, p. 110b protein levels in skeletal muscle of type 2 diabetic subjects, Diabetes, 51, 443, 10.2337/diabetes.51.2.443
Mayerson, 2002, The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes, Diabetes, 51, 797, 10.2337/diabetes.51.3.797
Miyazaki, 2002, Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes mellitus, Diabetes Care, 25, 517, 10.2337/diacare.25.3.517
Berkowitz, 1996, Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM, Diabetes, 45, 1572, 10.2337/diab.45.11.1572
Finegood, 2001b, β-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death, Diabetes, 50, 1021, 10.2337/diabetes.50.5.1021
Higa, 1999, Troglitazone prevents mitochondrial alterations, βcell destruction, and diabetes in obese prediabetic rats, Proc Natl Acad Sci USA, 96, 11513, 10.1073/pnas.96.20.11513
Willson, 2000, The PPARs: from orphan receptors to drug discovery, J Med Chem, 43, 527, 10.1021/jm990554g
Berger, 2002, The mechanisms of action of PPARs, Annu Rev Med, 53, 409, 10.1146/annurev.med.53.082901.104018
Saad, 2004, Ragaglitazar Dose-Ranging Study Group. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm, Diabetes Care, 27, 1324, 10.2337/diacare.27.6.1324
Ren, 2002, PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis, Genes Dev, 16, 27, 10.1101/gad.953802
Tontonoz, 1994, Stimulation of adipogenesis in fibroblasts by P, PAR_2, a lipid-activated transcription factor, Cell, 79, 1147, 10.1016/0092-8674(94)90006-X
Rosen, 1999, PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro, Mol Cell, 4, 611, 10.1016/S1097-2765(00)80211-7
Hallakou, 1997, Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa /fa rats, Diabetes, 46, 1393, 10.2337/diabetes.46.9.1393
Ribon, 1998, Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene, Proc Natl Acad Sci USA, 95, 14751, 10.1073/pnas.95.25.14751
Mori, 1999, Effects of troglitazone on body fat distribution in type 2 diabetic patients, Diabetes Care, 22, 908, 10.2337/diacare.22.6.908
Kelley, 1999, Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes, Diabetes Care, 22, 288, 10.2337/diacare.22.2.288
Kawai, 1999, Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes, Metabolism, 48, 1102, 10.1016/S0026-0495(99)90122-1
Gastaldelli, 2000, Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study, Diabetes, 49, 1367, 10.2337/diabetes.49.8.1367
Jacobs, 1999, Hearing H-U. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects, Diabetes, 48, 1113, 10.2337/diabetes.48.5.1113
Martin, 1996, Effects of acute and chronic exercise on fat metabolism, Exercise Sport Sci Rev, 24, 203, 10.1249/00003677-199600240-00009
Abernethy, 1990, Acute and chronic responses of skeletal muscle to endurance and sprint exercise, A Rev Sports Med, 10, 365, 10.2165/00007256-199010060-00004
Kelley, 2002, Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes, Diabetes, 51, 2944, 10.2337/diabetes.51.10.2944
Itani, 2002, Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha, Diabetes, 51, 2005-, 10.2337/diabetes.51.7.2005
Ellis, 2000, Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle, Amj Physiol, 279, E554
Mora, 2002, An adipocentric view of signaling and intracellular trafficking, Diabetes Metab Res Rev, 18, 345, 10.1002/dmrr.321
Song, 2002, Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules, Biochem Biophy Res Commun, 299, 291, 10.1016/S0006-291X(02)02551-2
Fonseca, 1998, Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus, J Diabetes Complications, 12, 181, 10.1016/S1056-8727(97)00109-8
Yu, 2002, The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects, Diabetes, 51, 2968, 10.2337/diabetes.51.10.2968
Sreenan, 1996, Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone, Am J Physiol, 271, E742
Smith, 2000, Rosiglitazone prevent the onset of hyperglycemia and proteinuria in the Zucker diabetic fatty rat, Diabetes Obesity Metab, 2, 363, 10.1046/j.1463-1326.2000.00099.x
Finegood, 2001, Beta-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death, Diabetes, 50, 1021, 10.2337/diabetes.50.5.1021
Lupi, 2002, PPARγ ligand-specificity in the modulation of insulin release from isolated human islets in response to fatty acid incubation, Diabetologia, 45, A161
Marselli, 2002, Rosiglitazone partially prevents free fatty acid-induced cytotoxicity of human pancreatic islet cells, Diabetologia, 45, A161
Buchanan, 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796